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Expression and Immunity
New Findings on Ahr Interactions
The transcription factor aryl hydrocarbon receptor (Ahr) can acti-
vate a multitude of genes that regulate the growth and division of
cells, including processes leading to cancer. To date, little is
known about the biochemical processes that mediate the activa-
tion of Ahr receptors in the body, or about the endogenous lig-
ands that bind to and activate these receptors. This month,
researchers from the University of Louisville, Texas A&M
University, and the University of New Mexico, under the leader-
ship of Charles D. Johnson, report on microarray analyses that
illuminate the complexity of Ahr interactions and thus provide a
focus for future experiments [EHP 112:403–412]. These results
include a previously unknown relationship between Ahr and genes
involved in the activation of the immune system. 
The researchers modeled the identification of relevant compo-
nents of the biological response to Ahr ligands using transcriptional
profiles of cells from murine embryonic heart, kidney, and vascular
smooth muscle cells. The data were analyzed using methods devel-
oped at the Texas A&M University Genomic Signal Processing
Laboratory to decipher multivariate, nonlinear relationships
among genes. 
The analysis focused on 200 of the 12,000 clones on the
microarrays that showed the greatest changes in response to hydro-
carbon exposures. The changes in each of these genes were quanti-
fied in relationship to five target genes, selected because they are
known to respond to ligands of Ahr. The first target gene was Ahr
itself. The second was Cyp1b1, which is involved in the synthesis of
steroids.The third was Igfbp-5, which regulates the functions of the
bones, kidneys, and mammary glands. The fourth was Lox, which
transcribes a copper-containing enzyme involved in the creation of
connective tissue. And the fifth was Opn, which transcribes osteo-
pontin, a protein involved in the mineralization of bone and a com-
ponent of human atherosclerotic plaques.
Activity in all five target genes was related to some degree; when
one was expressed, so were the other
four. The analysis was not designed to
determine whether activated genes were
upstream or downstream of each
other—in other words, which of a given
set of genes initiated a reaction.
The expression of Ahr was most
closely linked to that of lymphocyte
antigen 6, locus e, which is involved in
the activation of T cells. This relation-
ship had not been predicted by previous
studies and helps fill a gap in the map of
relationships among Ahr and retinoids
(forms of vitamin A). Lymphocyte anti-
gen 6e responds to the presence of
retinoic acid, and recent research has
shown that Ahr controls the expression
of genes that metabolize this compound.
Thus, computational strategies allowed
the delineation of connections between
Ahr and retinoic acid that otherwise
could not have been predicted in the
absence of biological information.
In other relationships found in this
study, Cyp1b1 was best predicted by the
gene that codes for spleen tyrosine
kinase, which participates in signaling
leading to activation of the transcription
factor NF-κB. Igfbp-5 was most fre-
quently predicted by Opn; Lox was best
predicted by lymphocyte antigen 6 com-
plex, locus H; and Opn was most often
predicted by brain-derived neurotrophic
factor, interleukin 6, and proliferin.  
The authors write that the computa-
tional approach they used allowed them
to begin constructing gene networks
that define broad-ranging interactive
biological relationships. “Although the
biological bases for these theoretical rela-
tionships must be investigated further,”
they conclude, “the number of possible
combinations is now reduced to a man-
ageable size that can be systematically
scrutinized using established molecular
methodologies.” –Kris Freeman
T with a twist. Adding an unexpected new element to the map of relationships between Ahr and
retinoids, recent microarray analysis reveals a novel link between this gene and T cells (above [red],
engaging with a virus [blue]). Science Selections
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Taking Stock of
Toxicogenomics
Mini-Monograph Offers Overview
Many early concerns about the utility of genomics technologies
have largely been put to rest, but several issues remain to be
resolved if toxicogenomics is to live up to its full potential. Chief
among these is the concern that, although there is a healthy spirit
of scientific collaboration and sharing within the toxicogenomics
community, standardized submission of and open access to data
has not yet been accomplished. The International Life Sciences
Institute Health and Environmental Sciences Institute (HESI)
Committee on the Application of Genomics to Mechanism-Based
Risk Assessment has been actively engaged in working on these
challenges by sharing experience, best operating practices, and data
to achieve standardization of toxicogenomics data. In this issue,
committee members William Pennie, Syril Pettit, and Peter Lord
present an overview of the committee’s research program [EHP
112:417–419]. The overview by Pennie and colleagues leads into
the mini-monograph appearing in this issue, which explores the
issues, challenges, and triumphs of using genomics in mechanism-
based risk assessment.
Established in 1999, the committee is a collaborative research
effort incorporating the unique perspectives and scientific talents
provided by its members from government, academia, and corporate
organizations representing the pharmaceutical, agrochemical, chemi-
cal, and consumer products industries. The committee has conduct-
ed and analyzed toxicogenomics experiments within the broad fields
of hepatotoxicity, nephrotoxicity, and genotoxicity with two goals in
mind: first, to determine whether known mechanisms of toxicity
could be associated with characteristic gene expression profiles; and
second, to identify technological and biological sources of variability
associated with toxicogenomic experimental protocols. The answers
to these questions helped the committee evaluate the usefulness of
gene expression technology for the purposes of risk assessment. 
There is an ongoing need for standardized submission of and
open access to data. Researchers also must have access, through pub-
lic repository databases, to standardized microarray data formats that
are linkable to toxicology data. To address these needs, the commit-
tee has developed a database in partnership with the European
Bioinformatics Institute. Based on the ArrayExpress database struc-
ture and Minimum Information About a Microarray Experiment
(or MIAME) data format standards, Tox-MIAMExpress will be
available to the public early in 2004, and will contain all of the data
generated by the committee’s research collaborations.
According to Pennie and coauthors, the committee’s experimen-
tal programs have in fact shown that toxicogenomics is an inherently
valuable tool for assessing toxicity. Specifically, they assert that the
value of toxicogenomics is supported by the research, which has
shown four things. First, patterns of gene expression relating to bio-
logical pathways are robust enough to allow insight into the mecha-
nisms of toxicity. Second, gene expression data can provide strong
information on topographic specificity. Third, dose-dependent
changes can be observed. Finally, concerns about oversensitivity of
the technology may be unfounded. 
The writers stress that it is important that microarray data results
be considered along with other biologic end points to understand
the mechanisms underlying toxicity. Pathway-level results will be
much more relevant for meaningful risk assessment than single gene
expression data, they write, particularly within the regulatory arena.
Clearly, toxicogenomics has come a long way in the short time
since the HESI committee was first established. As the mini-mono-
graph in this issue shows, the committee’s research portfolio and
collaborative approach have contributed significantly to rapid
progress in the field. In all likelihood, this contribution will contin-
ue, thanks to what the authors call “this collective experience for the
benefit of the regulators and regulated industries as well as for the
toxicology community as a whole.” 
The broad impression imparted by the papers, as expressed by
Pennie and colleagues in their overview of the program, is that
“genomics, and more specifically toxicogenomics, can no longer be
regarded as ‘new’ technology.” With increasing experience has come
increasing awareness that toxicogenomics is fast maturing. The field
has proven its value with solid research and significant additions to
the scientific knowledge base; its utility in mechanism-based risk
assessment is less likely to be considered tentative, potential, or
pending. –Ernie Hood
Working together. Researchers are sharing experience, best operating practices, and data to achieve standardization in toxicogenomics data.